Eikon Therapeutics Inc. Common Stock (EIKN)

FairStock Score: 15/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings power, honest accounting, and a margin of safety. Eikon is a clinical-stage biopharmaceutical company, not yet a commercial business. In the filed figures, revenue is not reported. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$88.4M and diluted EPS was -$1.63. In fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$83.0M and diluted EPS was -$2.46. In fiscal Q2 2025, the quarter ended 2025-06-30, net loss was -$105.2M. In fiscal Q1 2025, the quarter ended 2025-03-31, net loss was -$68.2M. The most recent comparable quarter improved, but fiscal Q1 2026 was worse than fiscal Q1 2025, so there is no stable earnings record. The moat is unproven: EIK1001, EIK1003, and EIK1004 are pipeline candidates, not products with pricing power. Financial health is poor by the supplied FairStock calculations: P/E -1.13, P/B 0.78, ROE -125.02%, ROCE -36.19%, Piotroski 0/9, Altman Z -0.51, and trailing FCF -$259.2M, a -71.2% FCF yield on the $364M market cap at the 2026-10-13 close. The P/B below one hints at asset value, but cash burn can erode book value quickly. FairStock's 15/100 score and no Lynch category, with only 0 years of filed results and 3 needed, confirm no track record. At $6.72, near the 52-week low of $6.71, the price may look cheap, but Graham would ask for demonstrated earning power or a hard asset cushion. Here I see neither. Until trial data, approvals, partnerships, or durable financing change the math, this is speculative biotech, not a value investment.

In plain English: Eikon Therapeutics is a drug company still testing its medicines in people. It has no reported revenue in the recent filings and is losing money while it develops cancer treatments. The shares trade below their accounting value, but because the business has no profits or track record, the low price looks uncertain rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer